| ²é¿´: 369 | »Ø¸´: 0 | ||
ÏôËàÇåÑïгæ (ÕýʽдÊÖ)
|
[ÇóÖú]
°ï·Òë
|
|
This is expected to result in a decrease in killer cell Ig-like receptor-mediated NK cell inhibition and an overestimation of NK cell activity compared with syngeneic tumor cell killing. Furthermore, PMN- and complement-mediated killing was performed with IgA2 or Fc-engineered EGFR Abs, respectively, because unmodified IgG1 Abs did not trigger tumor cell lysis by these effector sources (data not shown). Additionally, results from our studies against EGFR cannot easily be transferred to other target Ags, because incompletely defined target Ag characteristics determine whether these molecules are suitable for ADCC or CDC recruitment (45). For example, among different B cell-related Ags, HLA class II was particularly effective (46), whereas, for example, CD19 Abs required Fc engineering to trigger significant ADCC |
» ²ÂÄãϲ»¶
288»·¾³×¨Ë¶,Çóµ÷²ÄÁÏ·½Ïò
ÒѾÓÐ12È˻ظ´
ÇóÉúÎïѧѧ˶µ÷¼Á¡ª¡ª364·Ö
ÒѾÓÐ7È˻ظ´
288Çóµ÷¼Á£¬Ò»Ö¾Ô¸»ªÄÏÀí¹¤´óѧ071005
ÒѾÓÐ4È˻ظ´
11408,335·Ö£¬±¾¿Æ211£¬Çóµ÷¼Á£¬¿Éתרҵ
ÒѾÓÐ5È˻ظ´
0817»¯Ñ§¹¤³ÌÓë¼¼ÊõÇóµ÷¼Á£¬Ò»Ö¾Ô¸Öк£Ñó319
ÒѾÓÐ7È˻ظ´
Äܶ¯µ÷¼Á326ר˶
ÒѾÓÐ4È˻ظ´
295Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
285Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
315Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ6È˻ظ´














»Ø¸´´ËÂ¥